口服中药治疗射血分数保留型心力衰竭的Meta分析
该Meta分析检索7个数据库至2018年6月,纳入16项随机对照试验共1320例射血分数保留型心力衰竭患者,评估口服中药的有效性与安全性。结果显示口服中药辅助常规西药可能提高总体有效率(RR 1.17,95%CI 1.11~1.24,P<0.00001),但所纳入试验质量不足,尚不能确认或否定其疗效。
要点
- 口服中药辅助常规西药可能提高HFpEF总体有效率,但证据质量有限。
- BNP、NT-proBNP及MLHFQ改善结果异质性高,需谨慎解读。
- 6分钟步行试验未见显著差异,不良事件轻微且可缓解。
核心结论
- 由于所分析试验质量不足,目前尚不能确认或否定口服中药治疗HFpEF的疗效。
- 口服中药辅助常规西药可能提高总体有效率,但需更多严格设计的随机对照试验验证。
研究设计与样本
- 系统检索PubMed、EMBASE、Cochrane Library、CBM、万方、维普和CNKI,截至2018年6月3日。
- 纳入16项随机对照试验,共1320例射血分数保留型心力衰竭患者。
- 3项试验干预为中成药,其余为中药汤剂。
- 采用Cochrane偏倚风险评估工具进行质量评价,使用Revman 5.3分析。
主要发现
- 有限证据显示口服中药组BNP可能改善(MD -37.29,95%CI -53.08~-21.50,P<0.00001),但异质性高。
- 有限证据显示口服中药组NT-proBNP可能改善(MD -236.04,95%CI -356.83~-115.25,P=0.0001),但异质性高。
- 有限证据显示口服中药组MLHFQ可能改善(MD -9.94,95%CI -16.77~-3.11,P=0.004),但异质性高。
- 口服中药辅助治疗可能提高总体有效率(RR 1.17,95%CI 1.11~1.24,P<0.00001)。
- 6分钟步行试验在组间未见显著差异。
关键数值与推荐
- 总体有效率:RR 1.17,95%CI 1.11~1.24,P<0.00001,基于16项试验中12项存在担忧的Meta分析。
- BNP:MD -37.29,95%CI -53.08~-21.50,P<0.00001。
- NT-proBNP:MD -236.04,95%CI -356.83~-115.25,P=0.0001。
- MLHFQ:MD -9.94,95%CI -16.77~-3.11,P=0.004。
- 亚组分析显示中成药与汤剂对MLHFQ和NT-proBNP的效应方向不一致。
临床怎么用
- 口服中药可作为HFpEF常规西药治疗的辅助手段,但需结合患者具体情况谨慎使用。
- 临床决策时应关注症状、生活质量及利钠肽等指标,但需认识到证据异质性高。
- 不良事件如排便增多、乏力、心悸、水肿、咳嗽和低血压均轻微,停药或减量后可缓解。
局限性
- 所纳入试验质量不足,16项中12项存在偏倚担忧。
- 多数试验样本量小,干预措施异质性大(中成药与汤剂并存)。
- 缺乏长期随访和以主要终点为目标的高质量随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness and safety of oral Chinese herbal medicine (OCHM) for heart failure with preserved ejection fraction (HFpEF). METHODS: PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Chinese Biological Medicine Database (CBM), Wanfang Database, Chongqing VIP Information (VIP) and China National Knowledge Infrastructure (CNKI) were searched for appropriate articles from respective inceptions until June 3, 2018. Randomized controlled trials (RCTs) investigating the effectiveness of OCHM for the patients with HFpEF were eligible. Quality assessment was performed by employing the Cochrane Risk of Bias assessment tool. Papers were independently reviewed by two reviewers and analyzed using Cochrane software Revman 5.3. Dichotomous data were analyzed by relative risk (RR) with a 95% confidence interval (CI), while continuous variables were analyzed by using mean difference (MD) with 95% CI for effect size. RESULTS: A total of 16 RCTs involving 1,320 participants were identified. Fourteen of the trials used conventional Western medicine (CWM) as the control, the control of 1 trial was no treatment, and another was placebo. Three of the trials served Chinese patent medicine (CPM) as interventions, and other OCHM were Chinese medicine decoctions (CMDs). Only limited evidence showed experimental group with OCHM may get better effect on brain natriuretic peptide (BNP: MD -37.29, 95% CI -53.08 to -21.50, P<0.00001) or N terminal pro B type natriuretic peptide (NT-proBNP: MD -236.04, 95% CI -356.83 to -115.25, P=0.0001), Minnesota Living with Heart Failure questionnaire (MLHFQ, MD -9.94, 95% CI -16.77 to -3.11, P=0.004), but the results had high heterogeneities. With concerns on 12 of 16 trials, the meta-analysis found that the adjuvant therapy of OCHM might be more effective in increasing overall response rate (RR 1.17, 95% CI 1.11 to 1.24, P<0.00001), when compared with CWM alone. Subgroup meta-analysis between CPMs and CMDs showed that the two CPMs may have more therapeutic effect on MLHFQ, but not on NT-proBNP, and CMD came to the opposite conclusion. No significant differences were found between experimental groups and control groups on 6-min walk test (6MWT). Adverse events, such as more defecation, weakness, cardiopalmus, edema, cough and hypotension, were mild in all groups and disappeared after the easement of pharmacological intervention. CONCLUSIONS: Due to the insufficient quality of trials that were analyzed, it is not appropriate to confirm or deny the potency of OCHMs in treating HFpEF at the present time. More rigorously designed RCTs focusing on primary endpoints with long-term follow-up are warranted to validate the effect of OCHMs for patients with HFpEF.
引用
- Mei J, Xu H, Xu FQ, et al. Oral Chinese Herbal Medicine for Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. Chin J Integr Med. 2019. PMID: 31127505. doi:10.1007/s11655-019-2704-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。